18 August 2023
IQ-AI Ltd
("IQ-AI" or the "Company")
Update on Collaboration Agreement with Mayo Clinic
Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF) announces that the collaboration agreement signed with the Mayo Clinic for the development of IB Trax™ has concluded. The working relationship with the Mayo Clinic remains unchanged and will continue. As a corollary of the conclusion of the agreement, and in the spirit of the long-standing and continuing relationship between both parties, The Mayo Foundation has reverted the 396,241 shares previously issued to them per the terms of the agreement, and the Company has agreed with its Broker, Peterhouse Capital, to sell these shares in the market and to donate the entirety of the proceeds to charity.
--ENDS--
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
| IQ-AI Ltd Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda Tel: 020 7469 0930 |
| Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.